Gagnon Securities LLC Reduces Stake in GeneDx Holdings Corp. $WGS

Gagnon Securities LLC trimmed its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 5.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 253,534 shares of the company’s stock after selling 15,532 shares during the period. GeneDx comprises about 6.7% of Gagnon Securities LLC’s portfolio, making the stock its 2nd largest position. Gagnon Securities LLC’s holdings in GeneDx were worth $32,975,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in WGS. Goldman Sachs Group Inc. increased its holdings in shares of GeneDx by 4.5% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,220,502 shares of the company’s stock valued at $158,738,000 after acquiring an additional 52,322 shares during the period. Vanguard Group Inc. increased its holdings in shares of GeneDx by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 1,189,069 shares of the company’s stock valued at $154,650,000 after acquiring an additional 18,647 shares during the period. Franklin Resources Inc. increased its holdings in shares of GeneDx by 60.4% in the 4th quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company’s stock valued at $142,154,000 after acquiring an additional 411,607 shares during the period. Westfield Capital Management Co. LP increased its holdings in shares of GeneDx by 87.1% in the 4th quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company’s stock valued at $132,435,000 after acquiring an additional 474,167 shares during the period. Finally, ARK Investment Management LLC increased its holdings in shares of GeneDx by 35.3% in the 4th quarter. ARK Investment Management LLC now owns 604,561 shares of the company’s stock valued at $78,629,000 after acquiring an additional 157,582 shares during the period. 61.72% of the stock is currently owned by institutional investors.

GeneDx Trading Down 1.8%

Shares of NASDAQ:WGS opened at $59.92 on Friday. The business’s 50-day moving average is $54.95 and its 200 day moving average is $90.19. GeneDx Holdings Corp. has a 1 year low of $32.21 and a 1 year high of $170.87. The firm has a market capitalization of $1.78 billion, a P/E ratio of -22.36 and a beta of 1.96. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The company had revenue of $102.25 million for the quarter, compared to analysts’ expectations of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same period last year, the firm earned ($0.23) earnings per share. On average, research analysts predict that GeneDx Holdings Corp. will post -1 earnings per share for the current fiscal year.

Key Headlines Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Hedge fund manager Eli Casdin is reportedly adding to his GeneDx position, which may be seen as a sign that some sophisticated investors still view the stock as undervalued. Hedge Funder Eli Casdin Is Loading up on GeneDx Shares
• Neutral Sentiment: Several law firms continue to remind investors about the pending securities class action and the August 3 lead-plaintiff deadline. These notices keep the lawsuit in focus, but do not add new operational developments. Investor Alert: Pomerantz Law Firm Reminds Investors…
• Neutral Sentiment: Additional legal updates from Rosen, Faruqi & Faruqi, Schall, Robbins, and others reinforce the litigation backdrop tied to GeneDx’s Fabric Genomics acquisition and the Q1 2026 selloff. ROSEN, TOP RANKED INVESTOR COUNSEL…
• Negative Sentiment: GeneDx CEO Katherine Stueland and CFO Kevin Feeley both sold shares this week. The company says the sales were for tax withholding tied to vesting equity awards, but insider selling can still weigh on sentiment. CEO Form 4 Filing
• Negative Sentiment: The biggest overhang remains the securities class action alleging GeneDx misled investors about reimbursement rates, margin pressure, and the impact of the Fabric Genomics acquisition after a major stock drop and write-off tied to the deal. GeneDx Holdings (WGS) Faces Securities Class Action…

Insider Activity at GeneDx

In other news, CFO Kevin Feeley sold 1,266 shares of the business’s stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $53.77, for a total transaction of $68,072.82. Following the sale, the chief financial officer directly owned 36,486 shares of the company’s stock, valued at $1,961,852.22. The trade was a 3.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Katherine Stueland sold 3,639 shares of the business’s stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $53.77, for a total transaction of $195,669.03. Following the sale, the chief executive officer directly owned 96,123 shares in the company, valued at $5,168,533.71. This trade represents a 3.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders bought 2,256,420 shares of company stock valued at $93,144,340 and sold 77,287 shares valued at $5,153,215. 29.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on WGS. BTIG Research cut their price target on GeneDx from $170.00 to $90.00 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Craig Hallum reaffirmed a “buy” rating and issued a $85.00 price target on shares of GeneDx in a report on Tuesday, May 5th. Wall Street Zen lowered shares of GeneDx from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Piper Sandler reiterated an “overweight” rating and set a $130.00 price objective (down from $160.00) on shares of GeneDx in a report on Tuesday, February 24th. Finally, Zacks Research lowered GeneDx from a “strong-buy” rating to a “hold” rating in a report on Friday, April 24th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $96.43.

GeneDx Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.